#SFHS2608108ADecree of 30 March 2026 on the delisting of pharmaceutical specialties from the list of medicines approved for public authorities under Article L. 5123-2 of the Public Health Code
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French decree removes two long-acting injectable risperidone products (OKEDI 100 mg and OKEDI 75 mg) manufactured by Laboratoires ROVI from the official list of medicines approved for use by public authorities and various public services. The delisting takes effect four days after the decree's publication in the Journal officiel. These products are powder and solvent for prolonged-release injectable suspension in pre-filled syringes. After the effective date, these specific presentations can no longer be purchased or reimbursed under the public collective-use medicines framework governed by Article L. 5123-2 of the Public Health Code.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Two OKEDI risperidone presentations (100 mg and 75 mg prolonged-release injectables) are removed from the approved public authority medicines list
- Delisting takes effect on the 4th day following publication in the Journal officiel
- Radiation applies to codes CIP 34009 302 487 5 and 34009 302 487 4
+ 2 more changes with Pro
Obligations
What this law requires
Remove OKEDI 100 mg (risperidone) powder and solvent for prolonged-release injectable suspension (CIP code 34009 302 487 5 1) from the official list of medicines approved for public authorities and public services
Remove OKEDI 75 mg (risperidone) powder and solvent for prolonged-release injectable suspension (CIP code 34009 302 487 4 4) from the official list of medicines approved for public authorities and public services
Cease purchasing of OKEDI 100 mg and OKEDI 75 mg products under the public collective-use medicines framework effective four days after publication in the Journal officiel
Cease reimbursement of OKEDI 100 mg and OKEDI 75 mg products under the public collective-use medicines framework effective four days after publication in the Journal officiel
Publish this decree in the Journal officiel de la République française